Subscription & licensing questions
We can offer a free trial period to your organization in order to help you and your colleagues make the decision to subscribe to DIDB. Please contact us for more information.
Not at this time. Access to DIDB is granted to organizations via an annual subscription. The subscription allows for an unlimited number of users within an organization (or within a site for large organizations) to access DIDB.
DIDB is a research tool that was designed specifically for academic, pharmaceutical and regulatory scientists. DIDB is not intended as a primary clinical decision tool.
Questions about the data in DIDB
The data come from the scientific literature and the NDA reviews of the FDA-approved products. The majority of articles are indexed by NCBI PubMed; however, some articles are obtained from Embase.
No, regulatory documents covered in DIDB are limited to NDAs and BLAs from the FDA.
Most scientific publications are in English; therefore, the majority of data available in DIDB is from publications in English. However, some articles in DIDB are in other languages when published in native language of one of the team members, or when the (English) abstract provides sufficient information to include.
How do you choose the most relevant publications to enter and how do you guarantee coverage of relevant literature?
DIDB has detailed processes that have been developed over the last 20 years to ensure the most relevant data is captured in an unbiased manner by our curation process. The DIDB editorial team manually reviews the most relevant scientific journals, performs queries of NCBI PubMed, and verifies that relevant cited data are entered as well.
When information from an article or an NDA review is unclear, we check additional sources (e.g. clinicaltrials.gov for clinical DDI studies) or reach out to the authors of the article for clarification. Most of the time, we add comments within DIDB entries to explain possible discrepancies.
Yes, DIDB covers drug-drug, food-drug, and natural product-drug interactions.
Daily. As soon as the DIDB entries have been reviewed and validated, they become available to subscribers immediately.
All of the DIDB editorial work is conducted in-house, within the Department of Pharmaceutics at the University of Washington School of Pharmacy. Our team is comprised of pharmaceutical scientists, pharmacists, and physicians with expertise in drug metabolism, transport, pharmacokinetics, drug interactions, and clinical pharmacology.
DIDB includes mainly metabolism- and transporter-based pharmacokinetic interactions. However, other mechanisms (e.g. absorption-based DDIs) are also covered. Pharmacodynamic interactions which cannot be explained by changes in drug or metabolite exposure are not included.
Yes, modeling and simulation data that are performed in lieu of clinical studies are included.
A citation is either a publication or an NDA/BLA review and often contains multiple in vitro and/or clinical studies. An in vitro study refers to an experiment, which may contain one or multiple entries, whereas a clinical study may have one of multiple experiments and each experiment entered in DIDB is referred to as an entry.
DIDB application specific questions
To retrieve all data involving cannabinoids use the following queries: Basic Queries > Therapeutic Class Queries > One Therapeutic Class, and type in “Cannabinoids”, select between object or precipitant and “in vitro” and/or “in vivo”.
Currently in vitro transporter induction data is not included, but we are working on adding this module in the future when experimental protocols are well standardized and guidance from regulatory agencies is available. However, clinical transporter DDIs involving transporter induction are included in DIDB.
You can watch our tutorial documents and/or videos for tips. If you still have questions, feel free to contact us for assistance.